Expert Review of Anticancer Therapy
IF
3.57
Papers
2668
Papers 2825
1 page of 283 pages (2,825 results)
Newest
#1Matteo SantoniH-Index: 44
#2Roberto Iacovelli (Agostino Gemelli University Polyclinic)H-Index: 32
Last. Marianna Nuti (Sapienza University of Rome)H-Index: 24
view all 0 authors...
INTRODUCTION Altered receptor tyrosine kinase (RTK) signaling contributes to tumorigenesis and suppression of immune-mediated destruction of cancer cells. Cabozantinib is an oral tyrosine kinase inhibitor that inhibits several RTKs involved in tumorigenesis, and is approved for the treatment of patients with progressive metastatic medullary thyroid cancer, advanced renal cell carcinoma, and hepatocellular carcinoma that has been previously treated with sorafenib. AREAS COVERED We present an up-t...
Source
Introduction null Glioblastoma is a highly aggressive brain tumor with an extremely poor prognosis. Genetic characterization of this tumor has identified alterations with prognostic and therapeutic impact, and many efforts are being made to improve molecular knowledge on glioblastoma. Invasive procedures, such as tumor biopsy or radical resection, are needed to characterize the tumor. null Areas covered null The role of microRNA in cancer is an expanding field of research as many microRNAs have ...
Source
#1Frederick W. Thielen (EUR: Erasmus University Rotterdam)H-Index: 5
#2Marie-Jose Kersten (UvA: University of Amsterdam)H-Index: 17
Last. Hedwig M. Blommestein (EUR: Erasmus University Rotterdam)H-Index: 10
view all 0 authors...
BACKGROUND Efficacy of lenalidomide plus rituximab (R-LEN) compared to rituximab monotherapy (R-mono) for patients with previously treated follicular lymphoma (FL) was investigated in AUGMENT (NCT01938001). Our aim was to evaluate the cost-effectiveness of R-LEN versus R-mono in this setting from a Dutch perspective. METHODS Cost-effectiveness was assessed through a partitioned survival model with three health states from three perspectives (i.e. societal, healthcare and societal including futur...
Source
INTRODUCTION In the last decade, there have been substantial changes in the management of metastatic renal cell carcinoma (mRCC) with combined regimens with immune checkpoint inhibitors (ICI) replacing targeted therapies. These combined regimens include the combination of cabozantinib plus nivolumab. AREAS COVERED Here, we provide an overview of clinical trials evaluating the combination of cabozantinib and nivolumab and the current clinical data on mechanism of action, pharmacokinetics, efficac...
Source
Introduction null Avapritinib (formerly known as BLU-285) is an orally available type I tyrosine kinase inhibitor that, in 2020, obtained regulatory approval for the treatment of patients with gastrointestinal stromal tumors (GISTs) harboring a primary mutation in PDGFRA exon 18, including the PDGFRA D842V mutation. null Areas covered null Herein, we comprehensively review the available efficacy and safety data on avapritinib, with the final goal of providing practical knowledge to both sarcoma ...
Source
#1Vincent CamusH-Index: 37
#2Camille Bigenwald (Institut Gustave Roussy)H-Index: 2
Last. Clémentine Sarkozy (Institut Gustave Roussy)
view all 6 authors...
Introduction null Primary Mediastinal Large B-Cell Lymphoma (PMBL) is a rare subtype of lymphoma, clinically and biologically distinct from diffuse large B-Cell Lymphoma (DLBCL) that shows overlapping features with classical Hodgkin Lymphoma (cHL). If first line strategies lead to 80-85% of curability, relapse occurs early with a chemo-refractory disease and a poor outcome. The presence of 9p24.1 rearrangement, conducting to the overexpression of the immune checkpoint molecules PDL1 and 2, have ...
Source
#1Jin-sheng Zhao (NKU: Nankai University)H-Index: 1
#2Yusheng Zhao (TJU: Tianjin University)H-Index: 1
Last. Fanzheng Meng (NKU: Nankai University)H-Index: 1
view all 5 authors...
Aim null To explore the clinical significance of Cystathionine beta-synthase (CBS) expression in gastric cancer (GC). null Research design and methods null CBS expression and clinicopathological/follow-up information of patients with gastric cancer undergoing operation were collected from The Cancer Genome Atlas (TCGA) database. The association of CBS expression with patients' overall survival (OS) was determined in the entire cohort and different subgroups. Validation was performed in two exter...
Source
#1Yujiao Wang (University of Electronic Science and Technology of China)
#2XinXing Zhang (University of Electronic Science and Technology of China)
Last. Dingxiu He (Sichuan University)
view all 4 authors...
Background null Long noncoding RNAs (lncRNAs) are associated with the survival of cancer patients. We constructed an immune-related lncRNA (irlncRNA) pair signature for stomach adenocarcinoma (STAD). null Research design and methods null irlncRNAs were identified via coexpression analysis with immune-related genes. Differentially expressed irlncRNAs (DEirlncRNAs) were paired. Least absolute shrinkage and selection operator (LASSO) and multivariate Cox proportional hazards regression methods were...
Source
Introduction null EGFR-tyrosine kinase inhibitors (TKIs) changed the natural history of EGFR-mutant advanced NSCLC patients, but acquired resistance is inevitable. New strategies are being tested to overcome or prevent the emergence of resistance mechanisms to first-line TKIs, among which combinations of TKIs with antiangiogenic agents. null Areas covered null We performed a literature search for preclinical and clinical data on the interplay and dual inhibition of EGFR/VEGF pathways, particular...
Source
#1Lothar Bergmann (Praxis)H-Index: 51
#2Sarah Weber (Goethe University Frankfurt)H-Index: 4
Last. Marit Ahrens (Goethe University Frankfurt)H-Index: 3
view all 4 authors...
Introduction: Non-clear cell renal cell carcinoma (nccRCC) represents a highly heterogenous group of kidney cancer entities. As most clinical trials predominantly include patients with clear cell RCC (ccRCC), nccRCC treatment guidelines are mainly extrapolated from recommendations in ccRCC. Here, we review and elucidate current data on the pathologic classification and treatment of nccRCC.Areas covered: This article gives an overview of the WHO classification of RCC, showing the histological div...
Source
12345678910
Top fields of study
Cancer
Pathology
Oncology
Immunology
Chemotherapy
Radiation therapy
Medicine